Document › Details

Arquer Diagnostics Ltd.. (7/20/15). "Press Release: UroSens Announces Corporate Name Change and Rebranding to Arquer Diagnostics Ltd". Sunderland & Cambridge.

Organisations Organisation Arquer Diagnostics Ltd.
  Organisation 2 Cancer Research Technology Ltd. (CRT)
  Group Cancer Research UK (CRUK) (Group)
Products Product Mcm5-ELISA test (UroSens / Arquer Diagnostics)
  Product 2 MEDICA 2015 Düsseldorf
Index term Index term UroSens–SEVERAL: investment, 201501 financing round £2m led by Longwall Venture Partners
Person Person Campbell, Ian (UroSens 201501 CEO before Managing Director of Molecular Vision)
     


Rebranding reflects Company’s expansion into new oncology areas


UroSens Ltd, a diagnostic company developing novel, non-invasive urine-based immunoassay tests for the detection of cancer, has announced it has changed its name to Arquer Diagnostics Ltd (Arquer). As part of the name change, the Company has undergone a total brand refresh, which will see the implementation of a new visual identity and online presence to support Arquer’s future plans, evolution and growth, with immediate effect. To coincide with the rebranding, Arquer has launched a redesigned website www.arquerdx.com/
The rebranding reflects the progression of the Company’s strategic focus, beyond prostate and bladder cancer into diagnostics for multiple cancers of the urinogenitary tract, including colorectal and cervical cancers.

The Company has also announced that it has expanded its laboratory space at the North East Business and Innovation Centre, Sunderland, UK, from 300 sq ft to 1555 sq ft. The growth of the Company follows a £2 million ($3 million USD) investment in Arquer, in December last year, which has enabled expansion of the commercial and technical teams. The funding has also enabled Arquer to begin to commercialise its diagnostic test, the Mcm5-ELISA, which is expected to significantly reduce the number of patients undergoing invasive and costly biopsies, because it offers highly accurate diagnostic results from small amounts of body fluid.

Mcm5 (minichromosome maintenance complex component 5) is a protein which only appears when cells divide, and is a marker for the presence of dividing cancer cells. Arquer’s test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK.

Dr Ian Campbell, CEO at Arquer, commented: “This is a very exciting time for the Company. As we expand our focus into new areas we are taking the opportunity to update and strengthen how we represent ourselves, in line with our strategy. The rebranding represents our ambitions to bring our novel assay to the market, providing patients with a simple non-invasive test for cancers of the urinogenitary tract.”

Arquer will officially celebrate its new brand with clients and contacts at Medica 2015, 16-19th November, Düsseldorf.

   
Record changed: 2017-04-02

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Arquer Diagnostics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top